135 related articles for article (PubMed ID: 16138006)
21. Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer.
Borden LS; Clark PE; Lovato J; Hall MC; Stindt D; Harmon M; M Mohler R; Torti FM
Cancer; 2006 Sep; 107(5):1093-100. PubMed ID: 16888761
[TBL] [Abstract][Full Text] [Related]
22. Clinical predictors of androgen-independent prostate cancer and survival in the prostate-specific antigen era.
Oefelein MG; Ricchiuti VS; Conrad PW; Goldman H; Bodner D; Resnick MI; Seftel A
Urology; 2002 Jul; 60(1):120-4. PubMed ID: 12100936
[TBL] [Abstract][Full Text] [Related]
23. Perifosine in renal cell carcinoma.
Srivastava N; Cho DC
Expert Opin Investig Drugs; 2013 Feb; 22(2):285-91. PubMed ID: 23253151
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of perifosine in previously untreated patients with metastatic melanoma.
Ernst DS; Eisenhauer E; Wainman N; Davis M; Lohmann R; Baetz T; Belanger K; Smylie M
Invest New Drugs; 2005 Dec; 23(6):569-75. PubMed ID: 16034524
[TBL] [Abstract][Full Text] [Related]
25. A prospective, open label, randomized phase II trial of weekly docetaxel versus weekly vinorelbine as first line chemotherapy in patients with androgen independent prostate cancer.
Krainer M; Tomek S; Elandt K; Horak P; Albrecht W; Eisenmenger M; Höltl W; Schramek P; Stackl W; Zielinski C; Reibenwein J
J Urol; 2007 Jun; 177(6):2141-5; discussion 2145. PubMed ID: 17509302
[TBL] [Abstract][Full Text] [Related]
26. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration.
Tyrrell CJ; Iversen P; Tammela T; Anderson J; Björk T; Kaisary AV; Morris T
BJU Int; 2006 Sep; 98(3):563-72. PubMed ID: 16771791
[TBL] [Abstract][Full Text] [Related]
27. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
Sato N; Akakura K; Isaka S; Nakatsu H; Tanaka M; Ito H; Masai M;
Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
[TBL] [Abstract][Full Text] [Related]
28. A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer.
Van Ummersen L; Binger K; Volkman J; Marnocha R; Tutsch K; Kolesar J; Arzoomanian R; Alberti D; Wilding G
Clin Cancer Res; 2004 Nov; 10(22):7450-6. PubMed ID: 15569974
[TBL] [Abstract][Full Text] [Related]
29. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
[TBL] [Abstract][Full Text] [Related]
30. Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer.
Small EJ; Frohlich MW; Bok R; Shinohara K; Grossfeld G; Rozenblat Z; Kelly WK; Corry M; Reese DM
J Clin Oncol; 2000 Nov; 18(21):3595-603. PubMed ID: 11054432
[TBL] [Abstract][Full Text] [Related]
31. Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancer.
Liu G; Oettel K; Bailey H; Ummersen LV; Tutsch K; Staab MJ; Horvath D; Alberti D; Arzoomanian R; Rezazadeh H; McGovern J; Robinson E; DeMets D; Wilding G
Invest New Drugs; 2003 Aug; 21(3):367-72. PubMed ID: 14578686
[TBL] [Abstract][Full Text] [Related]
32. Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study.
Friedlander TW; Weinberg VK; Small EJ; Sharib J; Harzstark AL; Lin AM; Fong L; Ryan CJ
Urol Oncol; 2012; 30(4):408-14. PubMed ID: 20884247
[TBL] [Abstract][Full Text] [Related]
33. Phase II trial of estramustine and etoposide in androgen-sensitive metastatic prostate carcinoma.
Vaishampayan U; Fontana J; Du W; Hussain M
Am J Clin Oncol; 2004 Dec; 27(6):550-4. PubMed ID: 15577431
[TBL] [Abstract][Full Text] [Related]
34. Rapid androgen cycling as treatment for patients with prostate cancer.
Feltquate D; Nordquist L; Eicher C; Morris M; Smaletz O; Slovin S; Curley T; Wilton A; Fleisher M; Heller G; Scher HI
Clin Cancer Res; 2006 Dec; 12(24):7414-21. PubMed ID: 17189414
[TBL] [Abstract][Full Text] [Related]
35. Perifosine--a new option in treatment of acute myeloid leukemia?
Krawczyk J; Keane N; Swords R; O'Dwyer M; Freeman CL; Giles FJ
Expert Opin Investig Drugs; 2013 Oct; 22(10):1315-27. PubMed ID: 23931614
[TBL] [Abstract][Full Text] [Related]
36. Phase II study of vinorelbine in patients with androgen-independent prostate cancer.
Oudard S; Caty A; Humblet Y; Beauduin M; Suc E; Piccart M; Rolland F; Fumoleau P; Bugat R; Houyau P; Monnier A; Sun X; Montcuquet P; Breza J; Novak J; Gil T; Chopin D
Ann Oncol; 2001 Jun; 12(6):847-52. PubMed ID: 11484963
[TBL] [Abstract][Full Text] [Related]
37. A phase II study of fenretinide in patients with hormone refractory prostate cancer: a trial of the Cancer Therapeutics Research Group.
Moore MM; Stockler M; Lim R; Mok TS; Millward M; Boyer MJ
Cancer Chemother Pharmacol; 2010 Oct; 66(5):845-50. PubMed ID: 20082080
[TBL] [Abstract][Full Text] [Related]
38. Distinct prognostic role of prostate-specific antigen doubling time and velocity at emergence of androgen independence in patients treated with chemotherapy.
Daskivich TJ; Regan MM; Oh WK
Urology; 2007 Sep; 70(3):527-31. PubMed ID: 17905110
[TBL] [Abstract][Full Text] [Related]
39. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer.
Thalmann GN; Sikes RA; Chang SM; Johnston DA; von Eschenbach AC; Chung LW
J Natl Cancer Inst; 1996 Jun; 88(12):794-801. PubMed ID: 8637045
[TBL] [Abstract][Full Text] [Related]
40. Intermittent androgen deprivation: update of cycling characteristics in patients without clinically apparent metastatic prostate cancer.
Grossfeld GD; Chaudhary UB; Reese DM; Carroll PR; Small EJ
Urology; 2001 Aug; 58(2):240-5. PubMed ID: 11489710
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]